HOPA Members Join Efforts to Improve Quality of Care for those using Oral Anticancer Medications
Over the course of several months in 2023, the Pharmacy Quality Alliance (PQA) convened 23 national experts and patients to prioritize opportunities to improve the quality of care for individuals using oral anticancer medications (OAM).
The group’s number one measurement priority is a health plan performance measure to assess the degree to which patients take OAMs as prescribed.
HOPA members Emily Mackler, PharmD, BCOP, Director of Clinical Quality Initiatives at the Michigan Oncology Quality Consortium, and Ann Schwemm, PharmD, Associate Director of Clinical Oncology at Flatiron Health, Inc. were active participants. Benyam Muluneh, PharmD., BCOP, CPP, Assistant Professor at the UNC Eshelman School of Pharmacy was an observer.
In August, PQA released a report called Recommendations to Improve the Quality of Oral Anticancer Medication Use.
Read the full press release from the Pharmacy Quality Alliance:
PQA-Convened Experts and Patients Prioritize Opportunities to Improve Cancer Care Quality
